$DVAX
DYNAVAX TECHNOLOGIES CORP

2023 Q2 Form 10-Q Financial Statement

#000095017023016685 Filed on May 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $60.25M $46.93M
YoY Change -76.51% -58.83%
Cost Of Revenue $13.54M $14.71M
YoY Change -83.76% -63.19%
Gross Profit $46.71M $32.21M
YoY Change -73.01% -56.49%
Gross Profit Margin 77.53% 68.65%
Selling, General & Admin $37.07M $36.54M
YoY Change 2.47% 13.59%
% of Gross Profit 79.36% 113.44%
Research & Development $13.05M $13.61M
YoY Change 34.65% 22.62%
% of Gross Profit 27.93% 42.23%
Depreciation & Amortization $1.100M $1.013M
YoY Change 0.0% 2.84%
% of Gross Profit 2.35% 3.14%
Operating Expenses $50.12M $50.15M
YoY Change 9.26% 15.9%
Operating Profit -$3.405M -$30.25M
YoY Change -102.66% -198.33%
Interest Expense $1.688M $1.686M
YoY Change 0.3% 0.36%
% of Operating Profit
Other Income/Expense, Net -$71.00K $23.00K
YoY Change -277.5% -78.1%
Pretax Income $4.207M -$23.72M
YoY Change -96.75% -172.18%
Income Tax $800.0K $600.0K
% Of Pretax Income 19.02%
Net Earnings $3.431M -$24.33M
YoY Change -97.34% -174.05%
Net Earnings / Revenue 5.69% -51.85%
Basic Earnings Per Share $0.03 -$0.19
Diluted Earnings Per Share $0.03 -$0.19
COMMON SHARES
Basic Shares Outstanding 128.5M 127.7M
Diluted Shares Outstanding 152.1M 127.9M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $681.5M $652.0M
YoY Change 31.53% 29.56%
Cash & Equivalents $226.8M $174.4M
Short-Term Investments $454.7M $477.6M
Other Short-Term Assets $17.49M $15.63M
YoY Change -90.74% -92.94%
Inventory $53.09M $57.69M
Prepaid Expenses
Receivables $43.25M $101.7M
Other Receivables $2.108M $3.128M
Total Short-Term Assets $797.5M $830.1M
YoY Change -16.53% -11.74%
LONG-TERM ASSETS
Property, Plant & Equipment $37.44M $38.16M
YoY Change 3.19% 4.81%
Goodwill $2.039M $2.038M
YoY Change 4.14% -2.11%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $73.92M $73.94M
YoY Change 2097.89% 2045.08%
Total Long-Term Assets $139.0M $139.8M
YoY Change 105.6% 104.18%
TOTAL ASSETS
Total Short-Term Assets $797.5M $830.1M
Total Long-Term Assets $139.0M $139.8M
Total Assets $936.4M $969.9M
YoY Change -8.46% -3.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.246M $7.296M
YoY Change -34.54% -63.87%
Accrued Expenses $33.87M $27.83M
YoY Change -0.8% 72.79%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $44.86M $91.52M
YoY Change -87.0% -80.37%
LONG-TERM LIABILITIES
Long-Term Debt $222.1M $221.9M
YoY Change 0.5% 0.5%
Other Long-Term Liabilities $349.0K $352.0K
YoY Change 18.31% 27.54%
Total Long-Term Liabilities $349.0K $352.0K
YoY Change 18.31% 27.54%
TOTAL LIABILITIES
Total Short-Term Liabilities $44.86M $91.52M
Total Long-Term Liabilities $349.0K $352.0K
Total Liabilities $359.2M $406.2M
YoY Change -40.15% -43.7%
SHAREHOLDERS EQUITY
Retained Earnings -$945.1M -$948.5M
YoY Change -10.48% -19.92%
Common Stock $1.528B $1.516B
YoY Change 2.87% 2.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $577.2M $563.7M
YoY Change
Total Liabilities & Shareholders Equity $936.4M $969.9M
YoY Change -8.46% -3.87%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income $3.431M -$24.33M
YoY Change -97.34% -174.05%
Depreciation, Depletion And Amortization $1.100M $1.013M
YoY Change 0.0% 2.84%
Cash From Operating Activities $28.05M $27.62M
YoY Change 68.43% -154.76%
INVESTING ACTIVITIES
Capital Expenditures $751.0K $1.283M
YoY Change -125.78% -5.52%
Acquisitions
YoY Change
Other Investing Activities $25.47M -$51.05M
YoY Change -54.03% -76.27%
Cash From Investing Activities $24.72M -$52.33M
YoY Change -52.91% -75.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -294.0K -3.090M
YoY Change -128.6% -130.04%
NET CHANGE
Cash From Operating Activities 28.05M 27.62M
Cash From Investing Activities 24.72M -52.33M
Cash From Financing Activities -294.0K -3.090M
Net Change In Cash 52.47M -27.65M
YoY Change -25.23% -89.23%
FREE CASH FLOW
Cash From Operating Activities $28.05M $27.62M
Capital Expenditures $751.0K $1.283M
Free Cash Flow $27.30M $26.34M
YoY Change 39.52% -150.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001029142
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-34207
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Dynavax Technologies Corporation
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0728374
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2100 Powell Street
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 720
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Emeryville
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
128489060
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
174350000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
202004000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
477606000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
422391000
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12313000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
101738000
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
145130000
CY2023Q1 us-gaap Other Receivables
OtherReceivables
3128000
CY2022Q4 us-gaap Other Receivables
OtherReceivables
2385000
CY2023Q1 us-gaap Inventory Net
InventoryNet
57693000
CY2022Q4 us-gaap Inventory Net
InventoryNet
59446000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
15626000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
85629000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
830141000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
916985000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38159000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37596000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25433000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25745000
CY2023Q1 us-gaap Goodwill
Goodwill
2038000
CY2022Q4 us-gaap Goodwill
Goodwill
2006000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
210000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
207000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3311000
CY2023Q1 us-gaap Assets
Assets
969922000
CY2022Q4 us-gaap Assets
Assets
985850000
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94608
CY2023Q1 dei City Area Code
CityAreaCode
510
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
848-5100
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2023Q1 dei Trading Symbol
TradingSymbol
DVAX
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
7296000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3211000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
73941000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
581013000
CY2023Q1 dvax Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
5155000
CY2022Q4 dvax Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
4775000
CY2023Q1 dvax Coalition For Epidemic Preparedness Innovations Accruals
CoalitionForEpidemicPreparednessInnovationsAccruals
47401000
CY2022Q4 dvax Coalition For Epidemic Preparedness Innovations Accruals
CoalitionForEpidemicPreparednessInnovationsAccruals
107738000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27833000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30719000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3830000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3631000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
91515000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
150074000
CY2023Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3645000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3922000
CY2023Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
221855000
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
221578000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32131000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32801000
CY2023Q1 dvax Cepi Accrual Long Term
CepiAccrualLongTerm
60337000
CY2022Q4 dvax Cepi Accrual Long Term
CepiAccrualLongTerm
0
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
352000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
384000
CY2023Q1 us-gaap Liabilities
Liabilities
406190000
CY2022Q4 us-gaap Liabilities
Liabilities
404837000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
278000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
278000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
128472000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
128472000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
127604000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
127604000
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
128000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
128000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1516331000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1510518000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4200000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5438000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-948527000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-924195000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
969922000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
985850000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
563732000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
581013000
CY2023Q1 dvax Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
239000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
46925000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
113992000
CY2023Q1 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
14712000
CY2022Q1 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
39962000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13605000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11095000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36543000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
32172000
CY2023Q1 dvax Bad Debt Expense
BadDebtExpense
12313000
CY2022Q1 dvax Bad Debt Expense
BadDebtExpense
0
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
77173000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
83229000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-30248000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
30763000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
6597000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
261000
CY2023Q1 us-gaap Interest Expense
InterestExpense
1686000
CY2022Q1 us-gaap Interest Expense
InterestExpense
1680000
CY2023Q1 us-gaap Sublease Income
SubleaseIncome
1598000
CY2022Q1 us-gaap Sublease Income
SubleaseIncome
1609000
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1801000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
23000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
105000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23716000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
32859000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
616000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24332000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
32859000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.26
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.22
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
127921000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
124555000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
127921000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
149425000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24332000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
32859000
CY2023Q1 dvax Change In Unrealized Gain On Marketable Securities Available For Sale
ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
666000
CY2022Q1 dvax Change In Unrealized Gain On Marketable Securities Available For Sale
ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
-1272000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
572000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-625000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1238000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1897000
CY2023Q1 dvax Issuance Of Common Stock Upon Release Of Restricted Stock Awards Net Of Statutory Tax Withholdings
IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings
-5237000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
777000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23094000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
30962000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10034000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1238000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24332000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
563732000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
222374000
CY2022Q1 dvax Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
1122000
CY2022Q1 dvax Issuance Of Common Stock Upon Exercise Of Warrants
IssuanceOfCommonStockUponExerciseOfWarrants
24670000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
710000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7646000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1897000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
32859000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
287484000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24332000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
32859000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1013000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
985000
CY2023Q1 dvax Amortization Of Right Of Use Assets And Loss On Disposal Of Property And Equipment
AmortizationOfRightOfUseAssetsAndLossOnDisposalOfPropertyAndEquipment
642000
CY2022Q1 dvax Amortization Of Right Of Use Assets And Loss On Disposal Of Property And Equipment
AmortizationOfRightOfUseAssetsAndLossOnDisposalOfPropertyAndEquipment
743000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3498000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
181000
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1801000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
10034000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
7646000
CY2023Q1 dvax Bad Debt Expense
BadDebtExpense
12313000
CY2022Q1 dvax Bad Debt Expense
BadDebtExpense
0
CY2023Q1 dvax Non Cash Interest Expense
NonCashInterestExpense
1686000
CY2022Q1 dvax Non Cash Interest Expense
NonCashInterestExpense
1680000
CY2023Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-30336000
CY2022Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
5120000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1753000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
17703000
CY2023Q1 dvax Increase Decrease In Prepaid Manufacturing
IncreaseDecreaseInPrepaidManufacturing
0
CY2022Q1 dvax Increase Decrease In Prepaid Manufacturing
IncreaseDecreaseInPrepaidManufacturing
-21325000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1304000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9231000
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-677000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
49000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4096000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
16938000
CY2023Q1 dvax Increase Decrease In Cepi Accrual
IncreaseDecreaseInCepiAccrual
0
CY2022Q1 dvax Increase Decrease In Cepi Accrual
IncreaseDecreaseInCepiAccrual
-21478000
CY2023Q1 dvax Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
793000
CY2022Q1 dvax Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
806000
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-36661000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-5001000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-39589000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
27622000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50443000
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
185301000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
250375000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
134250000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
35250000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1283000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1358000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-52334000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-216483000
CY2023Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
CY2022Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
8455000
CY2023Q1 dvax Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net
ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
239000
CY2022Q1 dvax Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net
ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
1122000
CY2023Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
777000
CY2022Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
710000
CY2023Q1 dvax Payments For Taxes Related To Net Share Settlement Of Rsus
PaymentsForTaxesRelatedToNetShareSettlementOfRsus
4106000
CY2022Q1 dvax Payments For Taxes Related To Net Share Settlement Of Rsus
PaymentsForTaxesRelatedToNetShareSettlementOfRsus
0
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3090000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10287000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
151000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-134000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27651000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-256773000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
202211000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
436408000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
174560000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
179635000
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
32000
CY2022Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
87000
CY2023Q1 dvax Reclassification Of Contract Asset From Other Current Assets To Other Assets
ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets
71307000
CY2022Q1 dvax Reclassification Of Contract Asset From Other Current Assets To Other Assets
ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets
0
CY2023Q1 dvax Reclassification Of Cepi Accrual To Cepi Accrual Long Term
ReclassificationOfCepiAccrualToCepiAccrualLongTerm
-60337000
CY2022Q1 dvax Reclassification Of Cepi Accrual To Cepi Accrual Long Term
ReclassificationOfCepiAccrualToCepiAccrualLongTerm
0
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
926000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2007000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
278000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1173000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that may affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes, including amounts of revenues and expenses during the reported periods. Management’s estimates are based on historical information available as of the date of the unaudited condensed consolidated financial statements and various other assumptions we believe are reasonable under the circumstances. On an ongoing basis, we evaluate our estimates, judgments and methodologies. Significant estimates and assumptions in the unaudited condensed consolidated financial statements include those related to revenue recognition; accounts receivable; useful lives of long-lived assets, impairment of long-lived assets, including goodwill; valuation procedures for right-of-use assets and operating lease liabilities; valuation of inventory; balance sheet classification of convertible notes; income taxes, including the valuation allowance for deferred tax assets; research and development expenses; contingencies and share-based compensation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
174350000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
202004000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
179421000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
436189000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
210000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
207000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
214000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
219000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
174560000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
202211000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
179635000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
436408000
CY2023Q1 us-gaap Sublease Income
SubleaseIncome
1600000
CY2022Q1 us-gaap Sublease Income
SubleaseIncome
1600000
CY2023Q1 dvax Percentage Of Excess Rent Paid To Landlord
PercentageOfExcessRentPaidToLandlord
0.50
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
439791000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
439006000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
38555000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
38600000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
478346000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
477606000
CY2023Q1 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
CY2022Q1 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
CY2023Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
22400000
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
25517000
CY2023Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
19661000
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
23934000
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
15632000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
9995000
CY2023Q1 us-gaap Inventory Net
InventoryNet
57693000
CY2022Q4 us-gaap Inventory Net
InventoryNet
59446000
CY2023Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2031-03-31
CY2023Q1 us-gaap Lessee Operating Sublease Option To Extend
LesseeOperatingSubleaseOptionToExtend
The subtenant has no option to extend the sublease term
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
1388000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
1607000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1700000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1700000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3830000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3631000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32131000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32801000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
35961000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
36432000
CY2023Q1 dvax Lessor Sublease Rentals Payments To Be Received Remainder Of Fiscal Year
LessorSubleaseRentalsPaymentsToBeReceivedRemainderOfFiscalYear
4154000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
5324000
CY2023Q1 dvax Lessor Sublease Rentals Payments To Be Received Due Year Two
LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo
5684000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
7190000
CY2023Q1 dvax Lessor Sublease Rentals Payments To Be Received Due Year Three
LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree
5854000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6565000
CY2023Q1 dvax Lessor Sublease Rentals Payments To Be Received Due Year Four
LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour
6030000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5903000
CY2023Q1 dvax Lessor Sublease Rentals Payments To Be Received Due Year Five
LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive
6211000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6043000
CY2023Q1 dvax Lessor Sublease Rentals Payments To Be Received Due Thereafter
LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter
21500000
CY2023Q1 dvax Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
21240000
CY2023Q1 dvax Lessor Sublease Rentals Payments To Be Received
LessorSubleaseRentalsPaymentsToBeReceived
49433000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
52265000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
16304000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
35961000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y4M24D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y7M6D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.101
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.101
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12300000
CY2023Q1 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
269100000
CY2023Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1409000
CY2022Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1409000
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
277000
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
269000
CY2023Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
1686000
CY2022Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
1678000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
46925000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
113992000
CY2023Q1 us-gaap Contract With Customer Asset Change In Method Credit Loss Expense Reversal
ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal
71307000
CY2023Q1 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss Noncurrent
ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent
71307000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24332000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
32859000
CY2023Q1 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0
CY2022Q1 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-131000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24332000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
32728000
CY2023Q1 dvax Addition Of Undistributed Earnings Allocated To Participating Securities
AdditionOfUndistributedEarningsAllocatedToParticipatingSecurities
0
CY2022Q1 dvax Addition Of Undistributed Earnings Allocated To Participating Securities
AdditionOfUndistributedEarningsAllocatedToParticipatingSecurities
131000
CY2023Q1 dvax Fair Value Adjustments Of Warrants
FairValueAdjustmentsOfWarrants
0
CY2022Q1 dvax Fair Value Adjustments Of Warrants
FairValueAdjustmentsOfWarrants
-1801000
CY2023Q1 us-gaap Interest Expense Medium Term Notes
InterestExpenseMediumTermNotes
0
CY2022Q1 us-gaap Interest Expense Medium Term Notes
InterestExpenseMediumTermNotes
1259000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-24332000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
32317000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
127921000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
124555000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3001000
CY2023Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0
CY2022Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
326000
CY2023Q1 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0
CY2022Q1 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
21543000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
127921000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
149425000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37165000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8415000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
128471773
CY2022Q2 dvax Increase In Number Of Employee Stock Purchase Plan Shares Authorized For Issuance
IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance
15000000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9339000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.70
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y7M9D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
16291000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1663000
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.10
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
41000
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.84
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
29000
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.16
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
197000
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
22.83
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10735000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.56
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y10M2D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11820000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
10435000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
10.53
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y9M14D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
11808000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6281000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.89
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y11M26D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11049000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
10034000
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
7646000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
600000
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.026
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0

Files In Submission

Name View Source Status
0000950170-23-016685-index-headers.html Edgar Link pending
0000950170-23-016685-index.html Edgar Link pending
0000950170-23-016685.txt Edgar Link pending
0000950170-23-016685-xbrl.zip Edgar Link pending
dvax-20230331.htm Edgar Link pending
dvax-20230331.xsd Edgar Link pending
dvax-ex10_1.htm Edgar Link pending
dvax-ex31_1.htm Edgar Link pending
dvax-ex31_2.htm Edgar Link pending
dvax-ex32_1.htm Edgar Link pending
dvax-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
dvax-20230331_cal.xml Edgar Link unprocessable
dvax-20230331_lab.xml Edgar Link unprocessable
dvax-20230331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
dvax-20230331_pre.xml Edgar Link unprocessable
dvax-20230331_htm.xml Edgar Link completed
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending